KRIBIOLISA™ Vibecotamab ELISA

ELISA for the detection of Vibecotamab in human serum and plasma. Lead time for this kit is 5 weeks. About the kit: - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life: 1 year.Vibecotamab, a CD3-CD123 bispecific antibody, stimulates targeted T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. It is a full-length immunoglobulin molecule designed to be dosed intermittently. Multiple trials are ongoing to investigate its therapeutic effects in patients with AML.